Bateman ED, Aitchison JA, Summerton L, et al. The early onset of action of zafirlukast (Accolate) in patients with asthma. Am J Resp Crit Care Med 1997; 155: A663.
Calhoun WJ, Williams KL, Simonson SG, et al. Effect of zafirlukast (Accolate) on airway inflammation after segmental allergen challenge in patients with asthma. Am J Resp Crit Care Med 1997; 155: 662 abs.
Chung KF, Kennelly JC, Summerton L, et al. Compliance with an oral asthma treatment: electronic monitoring of twice daily dosing with zafirlukast. Allergy Clin Immunol Int 1997; 9 (S4): 241, Abs 880.
Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther 1997; 19: 675-90.
Holgate ST, Dahlen S-E (Eds). SRS-A to Leukotrienes. The Dawning of a New Treatment. Oxford: Blackwell; 1997. H102.
Laitinen LA, Laitinen A, Linqvist A, et al. Inhaled leukotriene E4 (LTE4) induces a persistent eosinophilia & airway obstruction which is reversed by regular zafirlukast treatment. Eur Respir J 1998; 12 (Suppl. 29): 55s, P423.
Lockhart A, Djaballah K, Dessanges JF, et al. The protective effect of zafirlukast against exercise-induced asthma. Eur Resp J 1997; 10 (s25): 419s.
Ringdal N, White M, Harris A. Addition of zafirlukast (Accolate) compared with a double dose of inhaled corticosteroids in patients with reversible airways obstruction, symptomatic on inhaled corticosteroids. Am J Respir Crit Care Med 1999; 159: A639.
Spector SL, Smith LJ, Glass M, et al. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Resp Crit Care Med 1994; 618-23. |
